传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LEGN 传奇生物

盘前交易 12-19 04:11:40 EST

21.28

-0.14

-0.65%

最高21.65	最低21.19	成交量184.52万
今开21.47	昨收21.42	日振幅2.15%
总市值39.30亿	流通市值17.32亿	总股本1.85亿
成交额3,935万	换手率2.27%	流通股本8,138万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LEGN","market":"US","secType":"STK","nameCN":"传奇生物","latestPrice":21.28,"timestamp":1766091600000,"preClose":21.42,"halted":0,"volume":1845234,"delay":0,"floatShares":81382003,"shares":184689564,"eps":-1.30264,"marketStatus":"盘前交易","change":-0.14,"latestTime":"12-19 04:11:40 EST","open":21.47,"high":21.65,"low":21.19,"amount":39348050.291568,"amplitude":0.021475,"askPrice":23.44,"askSize":100,"bidPrice":19.39,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.30264,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"adrRate":2,"listingDate":1591329600000,"exchange":"NASDAQ","adjPreClose":21.28,"postHourTrading":{"tag":"盘后","latestPrice":21.28,"preClose":21.28,"latestTime":"19:00 EST","volume":43728,"amount":930574.85,"timestamp":1766102413411},"volumeRatio":0.8837413929010727,"impliedVol":0.4608,"impliedVolPercentile":0.1406},"requestUrl":"/m/hq/s/LEGN","defaultTab":"news","newsList":[{"id":"2590792392","title":"港股异动 | 金斯瑞生物科技(01548)午后跌幅扩大逾11% 联营传奇生物隔夜股价大跌7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590792392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590792392?lang=zh_cn&edition=full","pubTime":"2025-12-09 13:53","pubTimestamp":1765259591,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技午后跌幅扩大逾11%，截至发稿，跌11.07%，报13.41港元，成交额3.07亿港元。消息面上，金斯瑞生物科技联营传奇生物隔夜股价大跌超7%，据媒体报道，在2025年美国血液学会 年会上，吉利德科学旗下 Kite Pharma 公布了下一代 CAR-T疗法 anito-cel 的最新临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HK0000306685.HKD","HK0000320264.USD","BK1576","BK4585","LEGN","HK0000320223.HKD","BK1583","BK1141","BK4505","01548","BK4139","HK0000306701.USD"],"gpt_icon":0},{"id":"1119581053","title":"传奇生物在2025年ASH大会上重点展示Carvykti®在多发性骨髓瘤的新数据及新型CAR-T平台在人类的首次应用结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119581053","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119581053?lang=zh_cn&edition=full","pubTime":"2025-12-07 03:01","pubTimestamp":1765047672,"startTime":"0","endTime":"0","summary":"传奇生物在2025年ASH大会上重点展示Carvykti®在多发性骨髓瘤的新数据及新型CAR-T平台在人类的首次应用结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","LEGN","BK4505"],"gpt_icon":0},{"id":"2583753060","title":"港股异动 | 金斯瑞生物科技(01548)跌超4% 联营传奇生物三季度净亏损收窄至3970万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583753060","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583753060?lang=zh_cn&edition=full","pubTime":"2025-11-13 13:58","pubTimestamp":1763013530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)逆势跌超4%，截至发稿，跌4.25%，报16.43港元，成交额2.21亿港元。消息面上，11月12日晚，金斯瑞生物科技的的联营公司传奇生物披露截至2025年9月30日止第三季度财务业绩。财务数据显示，截至2025年9月30日止三个月的净亏损为3970万美元，去年同期净亏损为1.253亿美元；调整后净亏损为1880万美元，去年同期调整后净亏损为4200万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","BK4588","HK0000320223.HKD","LEGN","BK1576","HK0000306685.HKD","01548","BK1141","BK4585","BK4139","BK1583","BK4505","HK0000306701.USD"],"gpt_icon":0},{"id":"1127477547","title":"异动解读 | 传奇生物第三季度亏损收窄 股价仍盘中大跌6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127477547","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127477547?lang=zh_cn&edition=full","pubTime":"2025-11-13 02:24","pubTimestamp":1762971868,"startTime":"0","endTime":"0","summary":"美国细胞疗法公司传奇生物周三盘中大跌6.46%，尽管公司第三季度财报显示亏损有所收窄。根据传奇生物公布的2025年第三季度未经审计财务报告，公司净亏损从去年同期的1.253亿美元收窄至3,970万美元。公司主打产品CARVYKTI的净销售额约为5.24亿美元，延续了强劲的环比增长势头。尽管财务状况有所改善，但市场对传奇生物的反应仍显谨慎。分析人士指出，虽然CARVYKTI销售强劲，但公司整体仍处于亏损状态，且研发费用持续上升。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LEGN"],"gpt_icon":0},{"id":"1131577985","title":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1131577985","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131577985?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:02","pubTimestamp":1761044561,"startTime":"0","endTime":"0","summary":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会，以继续推动公司的发展进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKRO","BK4505","BK4139","EXEL","LEGN","BK4532","BK4585","BK4588"],"gpt_icon":0},{"id":"2575564209","title":"港股异动丨金斯瑞生物科技涨超4% 传奇生物旗下CAR-T产品第三季度销售额达5.24亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575564209","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575564209?lang=zh_cn&edition=full","pubTime":"2025-10-15 16:03","pubTimestamp":1760515381,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技(1548.HK)盘中涨4.71%至16.67港元，年内累涨近70%，跑赢大盘表现(同期恒指累涨约30%)。消息面上，金斯瑞生物科技宣布，传奇生物科技股份有限公司(为公司联营公司已于2025年10月14日(纽约时间)向美国证券交易委员会提交6-K表格，并宣布，根据传奇与Janssen Biotech, Inc.(杨森)于2017年12月21日订立的合作及许可协议，CARVYKTI®于截至2025年9月30日止季度产生贸易销售净额约5.24亿美元。(格隆汇)\n\n\r\n            责任编辑：山上","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/10/15160353635849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4022","BK4139","BK4588","BK4230","01548","CAR","HK0000320223.HKD","BK4505","HK0000320264.USD","LEGN","HK0000306701.USD","BK1576","BK1141","BK1583","BK4585","HK0000306685.HKD"],"gpt_icon":0},{"id":"1129494241","title":"传奇生物：Carvykti在截至2025年9月30日的季度内实现净贸易销售额约5.24亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129494241","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129494241?lang=zh_cn&edition=full","pubTime":"2025-10-14 19:35","pubTimestamp":1760441718,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的文件显示，传奇生物旗下产品Carvykti在截至2025年9月30日的第三季度内，实现净贸易销售额约5.24亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","LEGN","BK4585","BK4139"],"gpt_icon":0},{"id":"1134616559","title":"传奇生物：Janssen将基于Cilta-Cel生产供应总成本加指定加价进行转移定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1134616559","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134616559?lang=zh_cn&edition=full","pubTime":"2025-10-08 04:10","pubTimestamp":1759867834,"startTime":"0","endTime":"0","summary":"传奇生物宣布，Janssen将根据Cilta-Cel的生产和供应总成本，加上指定的加价幅度来确定转移价格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","BK4139","BK4585","LEGN"],"gpt_icon":0},{"id":"1163365168","title":"传奇生物：美国子公司与Janssen Pharmaceuticals签署组件及产品供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1163365168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163365168?lang=zh_cn&edition=full","pubTime":"2025-10-08 04:06","pubTimestamp":1759867586,"startTime":"0","endTime":"0","summary":"传奇生物宣布，其美国子公司传奇生物美国有限公司已与Janssen Pharmaceuticals, Inc.签署组件和产品供应协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","BK4505","LEGN"],"gpt_icon":0},{"id":"2570035010","title":"创新药寻突围，“自研+引入”双轨战略能否重塑增长极？","url":"https://stock-news.laohu8.com/highlight/detail?id=2570035010","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570035010?lang=zh_cn&edition=full","pubTime":"2025-09-26 12:59","pubTimestamp":1758862756,"startTime":"0","endTime":"0","summary":"与此同时，2025年第二季度中国创新药对外BD首付款金额高达17.3亿美元，远超同期中国生物医药投融资金额6.9亿美元。根据药智网公布的数据，创新药从临床试验Ⅰ期到批准上市的可能性为12.69%，而整体研发成功率则更低。BD合作已成为创新药研发投入的新资金来源和主要资金来源。柳丹指出，未盈利创新药企需多元融资保障生存。今年上半年全球医药交易TOP10中，中国创新药资产的贡献率超过80%，且交易金额最高的资产也来自国内药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4505","ORR","02142","LEGN","BK4585","BK4139"],"gpt_icon":0},{"id":"2570802615","title":"鬼故事不一定能落地，但投资者的逻辑也应该慢慢变了","url":"https://stock-news.laohu8.com/highlight/detail?id=2570802615","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570802615?lang=zh_cn&edition=full","pubTime":"2025-09-26 07:28","pubTimestamp":1758842910,"startTime":"0","endTime":"0","summary":"创新药的鬼故事不一定能落地，但投资者却应该提前做好医药投资逻辑切换的准备。也就是说，虽然BD依然可以给药企带来诸多益处，但终有一天投资者会不再以BD作为交易决策的核心逻辑。“BD为王”的逻辑注定会逐渐淡化，并且在投资者的争议之中找到新的投资主线。所以投资者对于BD的关注应该适当降温，并做好达成新共识的准备。从研发预期，向商业化成绩落地，这将是中国创新药投资的大趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926073037a4446495&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926073037a4446495&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01276","09995","09688","02142","BK1191","LU0359201885.HKD","06618","06855","09969","02269","LU2543165471.USD","01801","01877","LEGN","LU1023057109.AUD","01952","02096","BK1161","LU0359201612.USD","06978","LU0359202008.SGD"],"gpt_icon":1},{"id":"2569229688","title":"近两个月股价最大跌幅达25%，二次上市会是传奇生物(LEGN.US)股价反弹良方？","url":"https://stock-news.laohu8.com/highlight/detail?id=2569229688","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569229688?lang=zh_cn&edition=full","pubTime":"2025-09-21 20:14","pubTimestamp":1758456864,"startTime":"0","endTime":"0","summary":"今年9月5日，彭博社援引知情人士消息称，由于投资者对制药商表现出浓厚兴趣，传奇生物正考虑在美国以外进行二次上市。在二次上市传闻披露后，传奇生物股价在9月8日至10日依旧走出“三连跌”，随后股价在低位波动。9月19日，公司收盘价34.01美元，近两个月股价最大跌幅已达25%。5月14日，传奇生物股价大跌10.55%，并在次日触及27.43美元低点，创下自2021年5月以来的股价新低。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LEGN","BK4588","BK4585","BK4139","BK4505"],"gpt_icon":0},{"id":"2566921919","title":"美股异动 | 中概医药股上涨 再鼎医药(ZLAB.US)涨超14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566921919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566921919?lang=zh_cn&edition=full","pubTime":"2025-09-11 22:41","pubTimestamp":1757601703,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","00013","BK4526","688235","BK1191","BK4139","LU1868836914.USD","LU0251142724.SGD","LU1969619763.USD","LEGN","159938","ONC","BK4552","IE0004091025.USD","IE00BFXG1179.USD","LU1894683264.USD","BK4531","LU0061475181.USD","LU0742534661.SGD","BK4007","BK4516","06160","LU0106831901.USD","HCM","LU1894683348.USD","LU1791807156.HKD","LU1868837300.USD","LU2237443895.HKD","LU1303224171.USD","LU2471134796.USD","BK1500","BK4550","IE00B19Z3581.USD","BK1587","LU1868837136.USD","BK4505","159992","LU2237443465.HKD","BK1574","LU0048573561.USD","LU2328871848.SGD","LU1668664300.SGD","09939","06978","LU1868836591.USD","LU2237443978.SGD","ZLAB","BK0239","09688","LU0096364046.USD"],"gpt_icon":0},{"id":"2566953419","title":"药明巨诺-B盘中异动 大幅下挫5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566953419","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566953419?lang=zh_cn&edition=full","pubTime":"2025-09-11 09:30","pubTimestamp":1757554218,"startTime":"0","endTime":"0","summary":"2025年09月11日早盘09时30分，药明巨诺-B股票出现波动，股价急速下挫5.07%。截至发稿，该股报4.870港元/股，成交量12.95万股，换手率0.03%，振幅1.75%。药明巨诺-B股票所在的生物技术行业中，整体跌幅为9.88%。此外，全球已有12款CAR-T产品上市。药明巨诺2025年上半年实现收入1.06亿元，同比增加22.5%；期内公司亏损同比扩大至2.67亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509110930209787d9f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509110930209787d9f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LEGN","BK4139","BK4505","BK4588","BK4585"],"gpt_icon":0},{"id":"2566260300","title":"传奇生物(LEGN)盘前涨超1% 据报公司考虑在美国以外进行第二上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2566260300","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566260300?lang=zh_cn&edition=full","pubTime":"2025-09-10 19:40","pubTimestamp":1757504451,"startTime":"0","endTime":"0","summary":"金吾财讯 | 传奇生物(LEGN)盘前涨超1%，截至发稿，报34.740美元。消息面上，据外媒报道，由于投资者对制药股表现出浓厚兴趣，传奇生物正考虑在美国以外进行第二上市，有可能选择香港、新加坡或伦敦。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"292312","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","LEGN","BK4585","BK4139"],"gpt_icon":0},{"id":"2566663847","title":"传奇生物，或将寻求第二上市融资：推进管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2566663847","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566663847?lang=zh_cn&edition=full","pubTime":"2025-09-09 10:20","pubTimestamp":1757384423,"startTime":"0","endTime":"0","summary":"任何文章转载需得到授权。传奇生物已与潜在顾问讨论了第二上市方案。截止发文前，公司市值66.59亿美元。离峰值下滑不少。2025年Q2，传奇生物CAR-T全球销售额为4.39亿美元，上半年销售额达8.08亿美元，较去年同期实现翻倍增长。基本由海外业绩贡献。产品线布局中，异体细胞疗法 BCMA*CD19 和体内CAR-T CD19*CD20也备受关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250909102228a4bccdac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250909102228a4bccdac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","BK4588","BK4585","LEGN"],"gpt_icon":0},{"id":"2565579122","title":"新股消息 | 传传奇生物(LEGN.US)拟在美国以外进行第二上市 香港为考虑地点之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2565579122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565579122?lang=zh_cn&edition=full","pubTime":"2025-09-08 10:07","pubTimestamp":1757297238,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","SG9999013478.USD","LU0877626530.USD","SG9999000343.SGD","SG9999014484.SGD","LU0831103253.SGD","BK6033","LU1920063259.USD","S68.SI","FSTM.SI","LU1119993845.HKD","LU0188438112.USD","LU2401740654.USD","SGXZ27511609.SGD","BK4588","LU2242646821.SGD","BK4139","LU2242652126.USD","SG9999003826.SGD","BK4505","BK1574","SG9999013486.USD","SG9999004360.SGD","SGXZ58947870.SGD","LU2242646235.USD","SG9999016042.SGD","BK6523","SG9999001135.SGD","ES3.SI","SG9999006266.SGD","LU1920062954.HKD","LU0898667661.SGD","SG9999014492.USD","BK6516","BK1191","01477","STI.SI","LU0205439572.USD","FSTAS.SI","LU0326948709.USD","SG9999001846.SGD","SG9999013460.SGD","LU0192582467.USD","IE00BKZH1Z71.USD","LEGN"],"gpt_icon":0},{"id":"2565457912","title":"新股消息 | 传传奇生物(LEGN.US)拟在美国以外进行第二上市 香港为考虑地点之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2565457912","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565457912?lang=zh_cn&edition=full","pubTime":"2025-09-08 10:07","pubTimestamp":1757297238,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，由于投资者对制药商表现出浓厚兴趣，传奇生物(LEGN.US)正考虑在美国以外进行第二上市。报道引述知情人士称，可能上市地点包括香港、新加坡和伦敦。尤其是在香港上市的情况下，第二上市可能有助于提升传奇生物的估值。报道指出，传奇生物仍在进行考虑中，可能决定不进行第二上市。传奇生物的代表不予置评。传奇生物成立于2014年，2020年于美国纳斯达克上市。其主营肿瘤治疗领域CAR-T细胞免疫疗法，旗舰产品西达基奥仑赛已获美国FDA批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1342448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LEGN","BK4505","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2561491750","title":"【光大医药&海外】金斯瑞生物科技（1548.HK）：传奇生物扭亏在即，授权收入大幅增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2561491750","media":"EBoversea","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561491750?lang=zh_cn&edition=full","pubTime":"2025-08-21 18:25","pubTimestamp":1755771942,"startTime":"0","endTime":"0","summary":"如需了解详细的证券研究信息，请具体参见光大证券研究所发布的完整报告。如因侵权行为给光大证券造成任何直接或间接的损失，光大证券保留追究一切法律责任的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250821184252a6f32ac1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250821184252a6f32ac1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4505","LEGN","BK4139"],"gpt_icon":1},{"id":"2561043761","title":"港股异动 | 金斯瑞生物科技(01548.HK)早盘涨超4% 礼新大额许可收入落地 传奇生物扭亏在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2561043761","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561043761?lang=zh_cn&edition=full","pubTime":"2025-08-21 11:23","pubTimestamp":1755746601,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK4588","BK1576","BK4585","BK4505","01548","HK0000320223.HKD","BK4139","HK0000320264.USD","HK0000306685.HKD","LEGN","BK1141","HK0000306701.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.legendbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0752},{"period":"1month","weight":-0.2767},{"period":"3month","weight":-0.3743},{"period":"6month","weight":-0.3741},{"period":"1year","weight":-0.3736},{"period":"ytd","weight":-0.346}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.018049},{"month":2,"riseRate":0.4,"avgChangeRate":0.004169},{"month":3,"riseRate":0.4,"avgChangeRate":-0.028053},{"month":4,"riseRate":0.8,"avgChangeRate":0.075373},{"month":5,"riseRate":0.4,"avgChangeRate":0.007649},{"month":6,"riseRate":1,"avgChangeRate":0.150366},{"month":7,"riseRate":0.666667,"avgChangeRate":0.033873},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.05555},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.023313},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.000245},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.020911},{"month":12,"riseRate":0,"avgChangeRate":-0.108011}],"exchange":"NASDAQ","name":"传奇生物","nameEN":"Legend Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"传奇生物,LEGN,传奇生物股票,传奇生物股票老虎,传奇生物股票老虎国际,传奇生物行情,传奇生物股票行情,传奇生物股价,传奇生物股市,传奇生物股票价格,传奇生物股票交易,传奇生物股票购买,传奇生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}